期刊
ANTIVIRAL RESEARCH
卷 47, 期 3, 页码 149-158出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/S0166-3542(00)00101-7
关键词
acyclovir (ACV); anti-HIV activity; anti-HSV activity; human macrophages; (R)PMPA
The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-I) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-I infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte-derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a now heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge! was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-I and HIV-1 replication in human macrophages. (C) 2000 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据